Orlando, FL -- (SBWIRE) -- 09/27/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Pacific Biosciences of California (NASDAQ:PACB), Venaxis Inc (NASDAQ:APPY).
Pacific Biosciences of California (NASDAQ:PACB) shares dropped 3.18% to $5.79. The company on Sept. 25 said it will get $35 million upfront and possibly $40 million more in a deal to make diagnostic products with Roche Diagnostics.
Menlo Park-based Pacific Biosciences will develop sequencing systems and consumable products under the deal, and will sell them exclusively to Roche, which has paid for an exclusive license to use the products for nucleic acid sequencing in human in vitro diagnostics.
Are investors worried about the recent updates with PACB? Find out with a free trend analysis HERE
Venaxis Inc (NASDAQ:APPY) shares declined 10.65% to $1.93. The company on Sept. 26 announced that the external Data and Safety Monitoring Board (DSMB) created as part of the Company's pivotal clinical trial for the APPY1 Test has recommended continuation of the pivotal clinical trial, based upon completion of the second and final futility analysis included in the clinical trial design.
The futility analysis, which consisted of an independent review of the validity, integrity, and clinical and scientific relevance of the ongoing study, was performed on the first 1,061 patients to complete the study.
Is APPY going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)